AstraZeneca agrees to acquire Modella AI to speed oncology drug development

Yahoo
Yahoo
4d ago
AstraZeneca is expanding AI integration in oncology R&D through its planned acquisition of Modella AI while advancing oncology and cardiometabolic pipeline programs and managing revenue pressure from loss of exclusivity.
AstraZeneca agrees to acquire Modella AI to speed oncology drug development
★

Key insights

  • 1

    Pharma companies are increasing AI-focused partnerships and investments: Eli Lilly and NVIDIA are set to establish a San Francisco Bay-based co-innovation lab with shared investment of up to $1bn to advance drug discovery using AI, and GSK’s chief scientific officer Tony Wood highlighted AI collaborations as key to early-stage R&D.

  • 2

    AstraZeneca is positioning ADCs as a revenue growth area: Sarin said AstraZeneca has eight wholly owned ADC assets in clinical development, and a 2024 GlobalData report forecast the ADC market will exceed $40bn by 2029.

A What happened
AstraZeneca agreed to acquire Boston-based Modella AI as part of a strategy to speed drug development across its oncology pipeline. The financial terms were undisclosed, and the deal builds on a collaboration that began with a research agreement in July 2025. AstraZeneca CFO Aradhana Sarin said AI is helping drive outcomes, boost efficiency and productivity, and accelerate innovation with measurable impact. Sarin said 16% oncology growth in the first nine months of 2025 increased confidence in reaching AstraZeneca’s $80bn total revenue target by 2030.

Topics

Technology & Innovation Artificial Intelligence Business & Markets Mergers & Acquisitions Health & Medicine Pharma & Biotech

Stay ahead with OwlBrief

A daily set of high-signal briefs — what happened, why it matters, what to watch next.

Create Free Account Sign In

Newsletter

Get OwlBrief in your inbox

A fast, high-signal digest of the day’s most important events — plus the context that makes them make sense.

A handful of briefs — before your coffee gets cold.

No spam. Unsubscribe anytime. We don’t sell your email.